Archives

  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis

    2026-04-29

    Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis Research

    Executive Summary: Z-VDVAD-FMK is an irreversible, cell-permeable peptide-based inhibitor with high selectivity for caspase-2, and inhibitory activity against caspase-3 and -7 (source: product_spec). It blocks apoptotic proteolysis by covalently binding the active site cysteine of target caspases (source: product_spec). In cell models, Z-VDVAD-FMK inhibits mitochondrial cytochrome c release and downstream apoptosis markers such as DNA fragmentation and PARP cleavage (source: internal_article). It demonstrates high solubility in DMSO (≥34.8 mg/mL), but is insoluble in ethanol and water (source: product_spec). APExBIO offers validated workflow recommendations and shipping protocols for reproducible apoptosis assay integration (source: product_spec).

    Biological Rationale

    Apoptosis is a tightly regulated cell death program essential for development, immune homeostasis, and cancer suppression. Caspases, a family of cysteine proteases, orchestrate the execution phase of apoptosis by cleaving key cellular substrates. Caspase-2 is among the earliest-activated initiator caspases, integrating stress signals before mitochondrial outer membrane permeabilization and cytochrome c release. Dysregulation of caspase-2 activity is implicated in tumorigenesis and resistance to chemotherapeutic agents (source: Padia et al., 2025).

    Targeted inhibition of caspase-2 enables researchers to dissect mitochondrial-dependent apoptotic pathways and distinguish caspase-dependent from caspase-independent cell death mechanisms, supporting mechanistic studies in cancer, neurodegenerative, and cardiovascular models (source: internal_article).

    Mechanism of Action of Z-VDVAD-FMK

    Z-VDVAD-FMK (benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone) is a synthetic, cell-permeable peptide inhibitor. It irreversibly inhibits caspase-2 by covalently modifying the active site cysteine residue. This prevents substrate proteolysis and disrupts downstream apoptotic signaling. Z-VDVAD-FMK also inhibits caspase-3 and -7 at higher concentrations, though with reduced potency compared to caspase-2 (source: product_spec).

    By blocking the caspase cascade upstream of mitochondrial events, Z-VDVAD-FMK prevents cytochrome c release and subsequent activation of executioner caspases, attenuating hallmark apoptosis markers such as DNA fragmentation and poly(ADP-ribose) polymerase (PARP) cleavage (source: internal_article).

    Evidence & Benchmarks

    • Z-VDVAD-FMK irreversibly inhibits caspase-2 activity in vitro and in cell-based assays, as demonstrated by loss of proteolytic cleavage of canonical substrates (source: product_spec).
    • In Jurkat T-lymphocytes treated with etoposide, Z-VDVAD-FMK prevents cytochrome c release from mitochondria and reduces apoptotic DNA fragmentation (source: internal_article).
    • In bovine brain microvessel endothelial cells, Z-VDVAD-FMK reduces oxyhemoglobin-induced apoptosis by inhibiting caspase-2 and -3, leading to decreased cell detachment and PARP cleavage (source: product_spec).
    • While Z-VDVAD-FMK prevents nuclear apoptosis induced by doxorubicin, it does not fully block cell death, indicating the persistence of caspase-independent mechanisms (source: product_spec).
    • High DMSO solubility (≥34.8 mg/mL) allows for concentrated stock solutions, facilitating reproducible dosage in cell-based workflows (source: product_spec).
    • The product is shipped with blue ice, and long-term storage of solutions below -20°C is recommended for up to several months (source: product_spec).

    For a broader mechanistic exploration and advanced protocol guidance, see this article, which provides unique insights into Z-VDVAD-FMK's role in disease modeling and host-pathogen interactions. This current dossier emphasizes technical boundaries and validated use cases in apoptosis and caspase activity measurement.

    Applications, Limits & Misconceptions

    Applications:

    • Dissecting caspase-dependent apoptotic pathways in cancer research and drug response assays (source: product_spec).
    • Studying mitochondrial cytochrome c release inhibition and its impact on cell death phenotypes (source: internal_article).
    • Caspase activity measurement in apoptosis assay workflows, including use as a negative control for caspase-2 function (source: internal_article).

    Limits:

    • Z-VDVAD-FMK is not selective for pyroptosis or necroptosis pathways; it cannot block caspase-1 or gasdermin D-mediated cell death (source: Padia et al., 2025).
    • It does not inhibit caspase-independent mechanisms of cell death, including those triggered by mitochondrial permeability transition or autophagy (source: product_spec).

    Common Pitfalls or Misconceptions

    • Misconception: Z-VDVAD-FMK is a pan-caspase inhibitor.
      Fact: It preferentially inhibits caspase-2, with weaker inhibition of caspase-3 and -7, and does not inhibit caspase-1 (source: product_spec).
    • Misconception: It is soluble in water or ethanol.
      Fact: Z-VDVAD-FMK is only soluble at ≥34.8 mg/mL in DMSO (source: product_spec).
    • Misconception: Inhibition of caspase-2 guarantees cell survival.
      Fact: Many cell death pathways are caspase-independent; Z-VDVAD-FMK does not fully prevent cell death in all models (source: product_spec).
    • Misconception: All apoptosis assays benefit equally from Z-VDVAD-FMK.
      Fact: Its use is optimal when caspase-2 is mechanistically relevant; otherwise, alternative inhibitors may be preferred (workflow_recommendation).

    Workflow Integration & Parameters

    Protocol Parameters

    • assay | DMSO solubility: ≥34.8 mg/mL | stock preparation | Ensures high-concentration stocks for dosing flexibility | product_spec
    • assay | 37°C warming for 10 minutes or sonication | stock preparation | Enhances solubility and homogeneity | product_spec
    • assay | -20°C storage | long-term stability | Preserves inhibitor potency for several months | product_spec
    • assay | Avoid long-term storage of reconstituted solutions | workflow integration | Reduces risk of degradation and activity loss | workflow_recommendation
    • assay | Use in apoptosis/caspase activity assays | mechanistic research | Supports mitochondrial and caspase-2 pathway dissection | product_spec

    For advanced integration, see this article, which complements this dossier by highlighting translational considerations and differences in caspase and mitochondrial signaling modulation.

    Conclusion & Outlook

    Z-VDVAD-FMK is a gold-standard irreversible caspase-2 inhibitor for mechanistic apoptosis research. Its validated use in apoptosis assays, caspase activity measurement, and mitochondrial cytochrome c release inhibition enables precise dissection of cell death pathways in cancer and related disease models (source: internal_article). APExBIO's rigorous documentation and protocol support facilitate reproducibility. As evidenced by recent research, distinguishing between caspase-dependent and -independent pathways remains critical for interpreting apoptosis assay results and for drug development targeting cell death mechanisms (source: Padia et al., 2025).

    For product details and technical support, visit the APExBIO Z-VDVAD-FMK page.